Skip to main content
. 2017 Feb 3;8(10):16605–16620. doi: 10.18632/oncotarget.15073

Figure 1. Evaluation of aromatase expression.

Figure 1

Aromatase (Cytochrome P450) protein expression was assessed in a panel of patient-derived GBM tumor xenograft samples and cell lines. Isolated protein lysates were provided from patient-derived glioblastoma xenografts (G46, G59, G64, G76, G79, G80, G84, G85 and G91) by the Mayo Clinic Brain Tumor SPORE [24–27]. These lysates, in addition to primary (MZ-327 and RN1) and recurrent (MZ-256 and MZ-304) GBM patient-derived cell lines were assessed by Western blotting for aromatase expression (50–55 kDa, Abcam, 1:250) with β-actin (1:5000) as a loading control. All clinical data pertaining to patient-derived glioblastoma xenograft tumor samples is provided in Supplementary Table 1.